



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose.

Symposium Director

Guenter Koehne, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Faculty

Adam Cohen, M.D., faculty for his educational activity is a researcher with Novartis, Janssen, GSK and Genentech. He is a consultant for GSK, BMS/Celgene, Genentech/Roche, Janssen, Pfizer, AbbVie, Arcellx and Ichnos. He receives royalties from Novartis. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Corey Cutler, M.D., faculty for this educational activity, is a consultant with Editas, Deciphera, Incyte, Mallinckrodt, Sanofi, Janssen, CTI Biopharma, Jazz, Equillium, Omeros and CSL Behring. He also has individual stocks/stock options with Cimeio and Oxford Immune Algorithmics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Aleksandra Filipovic, M.D., Ph.D., faculty for this educational activity, is an employee of Puretech Health. She is an advisor to SPCC Sharing Progress in Cancer Care. She is on the speakers bureau with Imperial College London and a practicing medical oncologist. She has indicated that her presentation and discussion will be limited to pre-clinical research, drug discovery and the methodologies of research. She will not make any care recommendations.

Nitin Jain, M.D., faculty for this educational activity is a researcher with Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, Servier, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Incyte, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics, Kite/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, TransThera Sciences and Novartis. He is a consultant with AbbVie, Adaptive Biotechnologies, AstraZeneca US, BeiGene, Bristol Myers Squibb, CareDx, Cellectis, Genentech, Inc., Ipsen US, Janssen Biotech, Kite/Gilead, Pharmacyclics, MEI Pharma, Precision BioSciences, Servier Pharmaceuticals and TG Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Matthew Matasar, M.D., faculty for this educational activity, is a researcher for Astra-Zeneca, Bayer, Genentech, IGM Biosciences, Janssen, Pharmacyclics, Roche and Seattle Genetics. He is a consultant with ADC Therapeutics, Astra Zeneca, Bayer, Daiichi Sankyo, Epizyme, F. Hoffmann-La Roche, Genentech, IMV Therapeutics, Juno Therapeutics, Karyopharm, Merck, MEI Pharma, Rocket Medical, Seattle Genetics, TG Therapeutics and Teva. He is an advisee for ADC Therapeutics, Astra Zeneca, Bayer, Daiichi Sankyo, Epizyme, F. Hoffmann-La Roche, Genentech, IMV Therapeutics, Juno Therapeutics, Karyopharm, Merck, MEI Pharma, Rocket Medical, Seattle Genetics, TG Therapeutics and Teva. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Alison Moskowitz, M.D., faculty for this educational activity, is a researcher for ADC Therapeutics, BeiGene, Miragen, Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte, and SecuraBio. She is a consultant with and member of the speakers bureau of Seagen, Affimed, Imbrium Therapeutics L.P./Purdue, Janpix, Merck, Seattle Genetics, and Takeda. She is an advisee for SAB member for Lymphoma Hub. She is on the scientific review committee for Gilead Science. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Siddhartha Mukherjee, M.D., faculty for this educational activity, is a consultant with Immuneel Therapeutics, Pure Tech, Cellenkos and Brahma Therapeutics. He has stock options with VOR. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Marcelo C. Pasquini, M.D., faculty for this educational activity is a researcher for BMS, Kite Pharma, Janssen and Novartis. He is a consultant for BMS. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Raajit Rampal, M.D., faculty for this educational activity, is an advisor for Morphosys/Constellation, CTI, Sierra/GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galecto, Pharmaessentia and Abbvie. He is on the speakers bureau for Protagonist and Karyopharm. He is an independent contractor with Morphosys, Stemline, Ryvu and Zentalis. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Paul Richardson, M.D., faculty of this educational activity, is a researcher with Oncopeptides, Celgene/BMS, Karyopharm and Takeda. He is a consultant with Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, Secura Bio, GSK, Astra Zeneca, Takeda and Janssen. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Michel Sadelain, M.D., faculty for this educational activity is a researcher for Takeda Therapeutics, Atarabio, Fate Therapeutics and Mnemo. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Craig Sauter, M.D., faculty for this educational activity is a researcher for Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. He is a consultant for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

David Scheinberg, M.D., faculty for this educational activity, is a researcher with Colummune, Artiva and Eureka. He is an advisee with Eureka, Colummune, Actinium, Repertoire, Oncopep, Pfizer, Sellas and Sapience. He receives royalties/patent benefits from Sellas, Actinium, Colmmune, Clase and Artiva. He has stock/stock options with Sellas, Actinium, Pfizer, Sapience, Eureka, Colmmune and ISRG. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Gunjan Shah, M.D., faculty for this educational activity is a researcher with Janssen, Amgen and Beyond Spring. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Robert Soiffer, M.D., faculty for this educational activity is a consultant with Cugene, Jasper, CSL Behring, Neovii and Vor Biopharma. He is on the board of directors of NMPD – Be the Match and Kiadis. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Eytan Stein, M.D., faculty for this educational activity is a consultant for Novartis, PinotBio, Janssen, Bristol Myers Squibb, Agios, Jazz, Menarini, Genentech, Genesis, AbbVie, Neoleukin, Gilead, Syndax, OnCusp, CTI Biopharma, Foghorn, Servier, Calithera, Daiichi, Aptose, Syros, Astellas, Ono Pharma, Blueprint. He received an honoraria: Kura. Safety Monitoring: Epizyme, Collectis. Research Funding: Eisai and Bristol Myers Squibb. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Wendy Stock, M.D., faculty for this educational activity is on the advisory board of Agios, Amgen, AstrZeneca, Beam, GSK, Jazz, Kite, Kronos, Kura, Morphosys, Newave, Pfizer, Pluristem, Servier and Syndax,. She has received honorariums from Up to Date, Jazz and Pfizer for research to practice. She has received service honorariums from American Society of Hematology. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Richard Stone, M.D., faculty for this educational activity is a consultant for AbbVie, AbbVie/Genentech, Actinium, Aptevo, Arog, AvenCell, BerGen Bio, BMS, Boston Pharmaceuticals, CTI Pharma, Epizyme, GSK, Janssen, Jazz, Kura Onc, Novartis, Syntrix, Syros and Takeda. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Marcel van den Brink, M.D. faculty for this this educational activity, is a researcher with Seres Therapeutics. He is a consultant with Merck & Co., Magenta Therapeutics, WindMIL Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Sevem, Priothera, Ceramedix, Lygenesis, Pluto Therapeutics and Da Volterra. He is and advisor with Rheos and GSK. He receives royalties/patent benefits from Wolters Kluwer. He has an executive role with DKMS. He has individual stocks/stock options with Seres Therapeutics, Notch Therapeutics and Pluto Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies* to disclose.

Aviva Abosch, M.D.,** receives research support from and is a consultant for Medtronic.

Kevin Abrams, M.D., is a consultant for Keystone Heart and Viz.AI, and is a stockholder in Cleerly and Viz.AI.

Guilherme Dabus, M.D., is a consultant for Penumbra, Microvention, Cerenovus, Stryker, Medtronic, Route92 and InNeuroCo, and a member of the speakers' bureau for Penumbra, Microvention, Stryker, Medtronic and Route92; also, he has an executive role with NeuroTactical Strategies and is a stockholder in Three Rivers Medical, NeuroFine, Deinde, InNeuroCo, Cleerly, Synchron, RIST, Amgen, Regeneron, eLum, Hyperion and GHIF.

Ian Del Conde Pozzi, M.D., is a member of the speakers' bureau for Abbott, Boston Scientific, Janssen and Pfizer Pharmaceuticals.

Kelly Foote, M.D.,** receives research support and fellowship support from and is a consultant to Boston Scientific and Medtronic; also, he receives research support from Functional Neuromodulation.

Michael Gomez, M.D., is a consultant for Depuy.

Italo Linfante, M.D.,** is a consultant for Medtronic, Cerenovus and Stryker, and a member of the speakers' bureau for Medtronic; also, he is a stockholder in InNeuroCo, Three Rivers Medical, Deinde Medical and Prolong Pharmaceuticals.

Michael McDermott, M.D., is a consultant for Deinde Medical and Stryker.

Srikanth Nagalla, M.D., is a consultant for Alexion Pharmaceuticals, Sanofi, Kedrion and Alnylam Pharmaceuticals, and a member of the speakers' bureaus for Sanofi, Sobi and Rigel; also, he is a stockholder in Gilead, Nine Meters Biopharma, Moderna, Novavax, Phio Pharmaceuticals and Therapeutic Solutions International. **Note:** The consulting relationships with Kedrion and Alnylam ended within the past 24 months.

Alberto Pinzon-Ardila, M.D, Ph.D., is a member of the speakers' bureau for SK Pharmaceuticals, Sunovion Pharmaceuticals and UCB.

Jose Javier Provencio, M.D.,** is an adviser to Cryothermics and is a consultant to and receives research support from Minnetronix.

Diego Torres-Russotto, M.D.,** is a consultant for Acorda, AbbVie-Allergan IPSEN, Kyowa Kirin, Revance, Sunovion and Teva.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*